AERIO News in brief Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

被引：0
|
作者：
Cochereau, D.
Tredaniel, J.
机构：
来源：
ONCOLOGIE | 2013年 / 15卷 / 01期
关键词：
BEVACIZUMAB; GEMCITABINE;
D O I：
10.1007/s10269-013-2248-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [21] MAINTENANCE THERAPY WITH PEMETREXED IMMEDIATELY FOLLOWING INDUCTION TREATMENT WITH PEMETREXED PLUS CISPLATIN FOR ADVANCED NON-SMALL-CELL NON-SQUAMOUS CARCINOMA OF THE LUNG: A SINGLE INSTITUTION'S EXPERIENCE
    Kim, D. H.
    Kinmond, A.
    Gilani, S.
    Giridharan, S.
    Sule-Suso, J.
    Jegannathen, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E13 - E13
  • [22] Safety, Resource Use, and Quality of Life in PARAMOUNT A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Gridelli, Cesare
    de Marinis, Filippo
    Pujol, Jean-Louis
    Reck, Martin
    Ramlau, Rodryg
    Parente, Barbara
    Pieters, Thierry
    Middleton, Gary
    Corral, Jesus
    Winfree, Katherine
    Melemed, Symantha
    Zimmermann, Anna
    John, William
    Beyrer, Julie
    Chouaki, Nadia
    Visseren-Grul, Carla
    Paz-Ares, Luis G.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : 1713 - 1721
  • [23] Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer
    Koba, Taro
    Minami, Seigo
    Nishijima-Futami, Yu
    Masuhiro, Kentaro
    Kimura, Hiromi
    Futami, Shinji
    Yaga, Moto
    Mori, Masahide
    Kagawa, Hiroyuki
    Uenami, Takeshi
    Kohmo, Satoshi
    Otsuka, Tomoyuki
    Yamamoto, Suguru
    Komuta, Kiyoshi
    Kijima, Takashi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 111 - 117
  • [24] A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L)
    Tanaka, Kaoru
    Morita, Satoshi
    Ando, Masahiko
    Yokoyama, Takuma
    Nakamura, Atsushi
    Yoshioka, Hiroshige
    Ishiguro, Takashi
    Miura, Satoru
    Toyozawa, Ryo
    Oguri, Tetsuya
    Daga, Haruko
    Ko, Ryo
    Bessho, Akihiro
    Tachihara, Motoko
    Iwamoto, Yasuo
    Hirano, Katsuya
    Nakanishi, Yoichi
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Okamoto, Isamu
    CANCER, 2020, 126 (16) : 3648 - 3656
  • [25] Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer
    Taro Koba
    Seigo Minami
    Yu Nishijima-Futami
    Kentaro Masuhiro
    Hiromi Kimura
    Shinji Futami
    Moto Yaga
    Masahide Mori
    Hiroyuki Kagawa
    Takeshi Uenami
    Satoshi Kohmo
    Tomoyuki Otsuka
    Suguru Yamamoto
    Kiyoshi Komuta
    Takashi Kijima
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 111 - 117
  • [26] Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for previously untreated advanced non-squamous non-small cell lung cancer
    Uenami, T.
    Koba, T.
    Minami, S.
    Futami, Y.
    Masuhiro, K.
    Kimura, H.
    Futami, S.
    Yaga, M.
    Mori, M.
    Kagawa, H.
    Komo, S.
    Otsuka, T.
    Yamamoto, S.
    Komuta, K.
    Kijima, T.
    ANNALS OF ONCOLOGY, 2017, 28 : 141 - 141
  • [27] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Sakamori, Yuichi
    Nagai, Hiroki
    Ozasa, Hiroaki
    Kaneda, Toshihiko
    Yoshioka, Hiroshige
    Nakagawa, Hiroaki
    Tomii, Keisuke
    Okada, Asuka
    Yoshimura, Kenichi
    Hirabayashi, Masataka
    Hirai, Toyohiro
    ANTICANCER RESEARCH, 2020, 40 (05) : 2981 - 2987
  • [28] Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
    Hanna, Nasser H.
    Kaiser, Rolf
    Sullivan, Richard N.
    Aren, Osvaldo Rudy
    Ahn, Myung-Ju
    Tiangco, Beatrice
    Voccia, Isabelle
    von Pawel, Joachim
    Kovcin, Vladimir
    Agulnik, Jason
    Gaschler-Markefski, Birgit
    Barrueco, Jose
    Sikken, Patricia
    Schloss, Charles
    Kim, Joo-Hang
    LUNG CANCER, 2016, 102 : 65 - 73
  • [29] PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Paz-Ares, Luis G.
    de Marinis, Filippo
    Dediu, Mircea
    Thomas, Michael
    Pujol, Jean-Louis
    Bidoli, Paolo
    Molinier, Olivier
    Sahoo, Tarini Prasad
    Laack, Eckart
    Reck, Martin
    Corral, Jesus
    Melemed, Symantha
    John, William
    Chouaki, Nadia
    Zimmermann, Annamaria H.
    Visseren-Grul, Carla
    Gridelli, Cesare
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2895 - +
  • [30] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345